2006/540/EC: Commission Decision of  11 April 2006  on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2006 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council  (notified under document number C(2006) 1483)   (Text with EEA relevance)
Date: 2006-04-11
Institutions: European Commission
Subjects: aerosol, chemical product, pharmaceutical industry, reduction of gas emissions, tradeable emission permit

4.8.2006

EN

Official Journal of the European Union

L 214/35

II

(Acts whose publication is not obligatory)

COMMISSION

COMMISSION DECISION

of 11 April 2006

on the allocation of quantities of controlled substances allowed for essential uses in the Community
in 2006 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council

(notified under document number C(2006) 1483)

(Only the Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Slovenian, Spanish and Swedish
texts are authentic)

(Text with EEA relevance)

(2006/540/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty
Community,

establishing the European

Montreal Protocol’, sets out
the criteria used by the
Commission for determining any essential uses and
authorises the production and consumption necessary
to satisfy essential uses of controlled substances in each
Party.

Having regard to Regulation (EC) No 2037/2000 of
the
European Parliament and of the Council of 29 June 2000 on
Substances that Deplete the Ozone Layer (1), and in particular
Article 3(1) thereof,

(4)

Whereas:

(1)

(2)

The Community has already phased out the production
and consumption of chlorofluorocarbons, other
fully
halogenated chlorofluorocarbons, halons, carbon tetra-
chloride, 1,1,1-trichloroethane, hydrobromofluorocarbon
and bromochloromethane.

Each year
the Commission is required to determine
essential uses for these controlled substances, the quan-
tities that may be used and the companies that may use
them.

(5)

(3)

Decision IV/25 of the Parties to the Montreal Protocol on
Substances that Deplete the Ozone Layer, hereinafter ‘the

Decision XV/8 of the Parties to the Montreal Protocol
authorises the production and consumption necessary
to satisfy essential uses of controlled substances listed
in Annexes A, B and C (Group II and III substances) of
the Montreal Protocol for laboratory and analytical uses
as listed in Annex IV to the report of
the Seventh
Meeting of the Parties, subject to the conditions set out
in Annex II to the report of the Sixth Meeting of the
Parties, as well as Decisions VII/11, XI/15 and XV/5 of
the Parties to the Montreal Protocol.Decision XVII/10 of
the
the Parties
production
controlled
substance listed in Annex E of the Montreal Protocol
necessary to satisfy laboratory and analytical uses of
methyl bromide.

to the Montreal Protocol authorises
and

consumption

the

of

to

Pursuant to paragraph 3 of Decision XII/2 of the Parties
to the Montreal Protocol on measures to facilitate the
transition
chlorofluorocarbon-free Metered-Dose
Inhalers (MDIs), all Member States have notified (2) the
United Nations Environment Programme that chloro-
for the
fluorocarbons (CFCs) are no longer essential
manufacture of salbutamol CFC-MDIs for placing on
the market of the European Community.

(1) OJ L 244, 29.9.2000, p. 1. Regulation as

last amended by
Commission Regulation (EC) No 29/2006 (OJ L 6, 11.1.2006,
p. 27).

(2) www.unep.org/ozone/Information_for_the_Parties/

3Bi_dec12-2-3.asp

L 214/36

EN

Official Journal of the European Union

4.8.2006

Austria, Belgium, Czech Republic, Denmark, Estonia,
Germany, Greece, Hungary, Latvia, Lithuania, Norway,
Portugal, The Netherlands,
the Slovak Republic and
Slovenia have notified UNEP that the use of CFCs is
for the manufacture of MDIs
not considered essential
for placing on the market of the European Community
that contain the active ingredients belonging to the ther-
apeutic category of ‘short-acting beta agonist bronchiodi-
lators’, specifically terbutaline (1), fenoterol, orciprenaline,
reproterol, carbuterol, hexoprenaline, pirbuterol, clen-
buterol, bitolterol and procaterol.

the Czech Republic,

Belgium,
Estonia, Germany,
Hungary, Latvia, the Netherlands, the Slovak Republic,
Slovenia and Sweden have notified UNEP that use of
CFCs is not considered essential for the manufacture of
the European
MDIs
ingredients
Community
that
‘inhaled
belonging to the
steroids’,
specifically beclomethasone, dexamethasone,
flunisolide, fluticasone, budesonide (2) and triamcinolone.

for placing on the market of
contain
therapeutic

active
category of

the

fluticasone),

fluticasone),

(beclomethasone,

Denmark (beclomethasone,
Ireland (beclo-
methasone, fluticasone), Finland (beclomethasone, fluti-
(beclomethasone,
casone),
Italy
France
fluticasone, budesonide), Malta (fluti-
(beclomethasone,
(fluticasone, budesonide),
casone, budesonide), Portugal
Slovenia
budesonide),
fluticasone,
fluticasone) and the United
Spain (beclomethasone,
Kingdom (fluticasone) have notified UNEP that use of
CFCs is not considered essential for the manufacture of
the European
MDIs
for placing on the market of
Community
ingredients
that
contain
‘inhaled
belonging to the
therapeutic
steroids’ shown in parentheses after each Member State.

active
category of

the

the Netherlands,

Belgium, the Czech Republic, Denmark, Estonia, Finland,
France, Germany, Greece, Latvia,
the
Slovak Republic and Slovenia have notified UNEP that
use of CFCs is not considered essential for the manu-
the
facture of MDIs for placing on the market of
European Community that contain the active ingredients
belonging to the therapeutic category of ‘non-steroidal
anti-inflammatories’,
specifically cromoglicic acid and
nedrocromil.

Portugal has notified UNEP that use of CFCs is not
for the manufacture of MDIs for
considered essential
placing on the market of
the European Community
the active ingredient cromoglicic acid.
that contains
Spain has notified UNEP that use of CFCs
is not
for the manufacture of MDIs for
considered essential
placing on the market of
the European Community
that contains the active ingredient nedrocromil.

(6)

the Netherlands,

Belgium, Cyprus, the Czech Republic, Denmark, Estonia,
Finland, Germany, Greece, Hungary,
Ireland, Latvia,
Malta,
the Slovak Republic, Spain,
Sweden and the United Kingdom have notified UNEP
for the
that use of CFCs is not considered essential
manufacture of MDIs for placing on the market of the
European Community that contain the active ingredients
belonging to the therapeutic category of ‘anticholinergic
bronchodilators’,
specifically ipatropium bromide and
oxitropium bromide.

Portugal has notified UNEP that use of CFCs is not
for the manufacture of MDIs for
considered essential
placing on the market of
the European Community
that contains the active ingredient ipatropium bromide.

Germany has notified UNEP that use of CFCs is not
for the manufacture of MDIs for
considered essential
placing on the market of
the European Community
that contain the active ingredients belonging to the ther-
apeutic category of ‘long-acting beta agonist bronchiodi-
lators’, specifically formoterol and salmeterol.

Italy has notified UNEP that use of CFCs
considered essential
placing on the market of
that contains the active ingredient formoterol.

is not
for the manufacture of MDIs for
the European Community

Germany and the Netherlands have notified UNEP that
use of CFCs is not considered essential for the manu-
the
facture of MDIs for placing on the market of
European Community that contain combinations of
active ingredients.

Article 4(4)(i)(b) of Regulation (EC) No 2037/2000
prevents CFCs from being used and placed on the
market unless they are considered essential under the
conditions described in Article 3(1) of that Regulation.
therefore
These non-essentiality determinations have
reduced the demand for CFCs used in MDIs that are
placed on the market of the European Community. In
addition, Article 4(6) of Regulation (EC) No 2037/2000
prevents CFC-MDI products being imported and placed
on the market unless the CFCs in these products are
considered essential under the conditions described in
Article 3(1).

The Commission has published a Notice (3) on 8 July
2005 to those companies in the Community of 25
Member States
the
request
Commission for the use of controlled substances for
essential uses in the Community in 2006 and has
received declarations on intended essential uses of
controlled substances for 2006.

consideration by

that

(1) Except Denmark.
(2) Except Sweden.

(3) OJ C 168, 8.7.2005, p. 20.

4.8.2006

EN

Official Journal of the European Union

L 214/37

(7)

(8)

For the purpose of ensuring that interested companies
in due time
and operators may continue to benefit
from the licensing system,
the
is appropriate that
present decision shall apply from 1 January 2006.

it

The quantity of controlled substances of Group VII
7.
(hydrobromofluorocarbons)
to Regulation (EC) No
subject
2037/2000 that may be used for essential laboratory uses in
the Community in 2006 shall be 4,49 ODP kilograms.

in this Decision are in
The measures provided for
accordance with the opinion of
the Management
Committee established by Article 18(1) of Regulation
(EC) No 2037/2000,

8.
The quantity of controlled substances of group IX (bromo-
chloromethane) subject to Regulation (EC) No 2037/2000 that
may be used for essential laboratory uses in the Community in
2006 shall be 13,308 ODP kilograms.

HAS ADOPTED THIS DECISION:

Article 2

Article 1

1.
The quantity of controlled substances of Group I (chloro-
fluorocarbons 11, 12, 113, 114 and 115) subject to Regulation
(EC) No 2037/2000 which may be used for essential medical
uses in the Community in 2006 shall be 539 000,00 ODP (1)
kilograms.

2.
The quantity of controlled substances of Group I (chloro-
fluorocarbons 11, 12, 113, 114 and 115) and Group II (other
fully halogenated chlorofluorocarbons) subject
to Regulation
(EC) No 2037/2000 which may be used for essential laboratory
uses in the Community in 2006 shall be 256 761,86 ODP
kilograms.

The chlorofluorocarbon metered-dose inhalers listed in Annex I
shall not be placed on markets where the Competent Authority
has determined chlorofluorocarbonsfor metered-dose inhalers
on those markets to be non-essential.

Article 3

During the period 1 January to 31 December 2006 the
following rules shall apply:

1. The allocation of essential medical use quotas for chloro-
fluorocarbons 11, 12, 113, 114 and 115 shall be to the
companies indicated in Annex II.

3.
The quantity of controlled substances of Group III (halons)
subject to Regulation (EC) No 2037/2000 that may be used for
essential
laboratory use in the Community in 2006 shall be
482,70 ODP kilograms.

2. The allocation of essential laboratory use quotas for chloro-
fluorocarbons 11, 12, 113, 114 and 115 and other fully
halogenated chlorofluorocarbons shall be to the companies
indicated in Annex III.

4.
The quantity of controlled substances of Group IV (carbon
tetrachloride) subject to Regulation (EC) No 2037/2000 that
may be used for essential
laboratory uses in the Community
in 2006 shall be 149 641,536 ODP kilograms.

3. The allocation of essential laboratory use quotas for halons

shall be to the companies indicated in Annex IV.

5.
The quantity of controlled substances of Group V (1,1,1-
trichloroethane) subject to Regulation (EC) No 2037/2000 that
may be used for essential
laboratory uses in the European
Union in 2006 shall be 754,00 ODP kilograms.

The quantity of controlled substances of Group VI (methyl
6.
bromide) subject to Regulation (EC) No 2037/2000 that may be
used for laboratory and analytical uses in the Community in
2006 shall be 300,00 ODP kilograms.

(1) Ozone-depleting Potential.

4. The allocation of essential laboratory use quotas for carbon
tetrachloride shall be to the companies indicated in Annex V.

5. The allocation of essential laboratory use quotas for 1,1,1-
indicated in

trichloroethane shall be to the companies
Annex VI.

6. The allocation of laboratory and analytical critical use quotas
for methyl bromide shall be to the companies indicated in
Annex VII.

L 214/38

EN

Official Journal of the European Union

4.8.2006

7. The allocation of essential laboratory use quotas for hydro-
bromofluorocarbons shall be to the companies indicated in
Annex VIII.

carbons, carbon tetrachloride, 1,1,1-trichloroethane, hydro-
bromofluorocarbons and bromochloromethane shall be as
set out in Annex X.

8. The

allocation of

for
bromochloromethane shall be to the companies indicated
in Annex IX.

laboratory use quotas

essential

Article 4

9. The essential use quotas for chlorofluorocarbons 11, 12,
113, 114 and 115, other fully halogenated chlorofluoro-

This Decision shall apply from 1 January 2006 and shall expire
on 31 December 2006.

This Decision is addressed to the following undertakings:

Article 5

3M Health Care Ltd
3M House Morley Street
Loughborough
Leicestershire LE11 1EP
United Kingdom

Boehringer Ingelheim GmbH
Binger Straße 173
D-55216 Ingelheim am Rhein
on behalf of Boehringer Ingelheim (France)

IVAX Ltd
Unit 301 Industrial Park
Waterford
Ireland

SICOR SpA
Via Terrazzano, 77
I-20017 Rho (MI)

Valvole Aerosol Research Italiana (VARI)
Spa — LINDAL Group Italia
Via del Pino, 10
I-23854 Olginate (LC)

Acros Organics bvba
Janssen Pharmaceuticalaan 3o
B-2440 Geel

Biosolove B.V.
Waalreseweg 17
5554 HA Valkenswaard
Nederland

Carlo Erba Reactifs-SDS
Z.I. de Valdonne, BP 4
F-13124 Peypin

Health Protection Inspectorate-Laboratories
Paldiski mnt 81
EE-10617 Tallinn

Honeywell Specialty Chemicals
Wunstorfer Straße 40
Postfach 100262
D-30918 Seelze

Bespak PLC
North Lynn Industrial Estate
King's Lynn
PE30 2JJ — Norfolk
United Kingdom

Chiesi Farmaceutici SpA
Via Palermo, 26/A
I-43100 Parma

Laboratorio Aldo Union SA
Baronesa de Maldá, 73
Espluges de Llobregat
E-08950 Barcelona

Valeas SpA Pharmaceuticals
Via Vallisneri, 10
I-20133 Milano

Airbus France
route de Bayonne 316
F-31300 Toulouse

Bie & Berntsen
Sandbækvej 7
DK-2610 Roedovre

CNRS — Groupe de Physique des Solides
Université Paris, 7 Denis Diderot & Paris
6 Pierre et Marie Curie
F-75251 Paris Cedex 5

Honeywell Fluorine Products Europe
Kempenweg 90
P.O. Box 264
6000 AG Weert
Nederland

Ineos Fluor Ltd
PO Box 13, The Heath
Runcorn Cheshire WA7 4QF
United Kingdom

4.8.2006

EN

Official Journal of the European Union

L 214/39

Institut Scientifique de Service Public (ISSeP)
Rue du Chéra, 200
B-4000 Liège

Katholieke Universiteit Leuven
Krakenstraat 3
B-3000 Leuven

LGC Promochem GmbH
Mercatorstraße 51
D-46485 Wesel

Merck KgaA
Frankfurter Straße 250
D-64271 Darmstadt

Ministry of Defense
Directorate Material RNL Navy
PO Box 2070
2500 ES The Hague
Nederland

Sanolabor d.d.
Leskovškova 4
SLO-1000 Ljubljana

Sigma Aldrich Chimie SARL
80, rue de Luzais
L'isle-d'abeau Chesnes
F-38297 Saint-Quentin-Fallavier

Sigma Aldrich Laborchemikalien
Wunstorfer Straße 40
Postfach 100262
D-30918 Seelze

Tazzetti Fluids S.r.l.
Corso Europa, 600/a
I-10088 Volpiano (TO)

VWR I.S.A.S.
201, rue Carnot
F-94126 Fontenay-sous-Bois

Done at Brussels, 11 April 2006.

Mallinckrodt Baker BV
Teugseweg 20
7418 AM Deventer
Nederland

Mikro+Polo d.o.o.
Lackova 78
SLO-2000 Maribor

Panreac Química SA
Riera de Sant Cugat 1
E-08110 Montcada I Reixac (Barcelona)

Sigma Aldrich Logistik GmbH
Riedstraße 2
D-89555 Steinheim

Sigma Aldrich Company Ltd
The Old Brickyard
New Road Gillingham SP8 4XT
United Kingdom

Sigma Aldrich Chemie GmbH
Riedstraße 2
D-89555 Steinheim

University of Technology Vienna
Institut of Industrial Electronics&Material Science
Gusshausstraße 27-29
A-1040 Wien

YA-Kemia Oy — Sigma Aldrich Finland
Teerisuonkuja 4
FI-00700 Helsinki

For the Commission

Stavros DIMAS
Member of the Commission

L 214/40

EN

Official Journal of the European Union

4.8.2006

ANNEX I

Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to
facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined
that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when
combined with following active ingredients:

Table 1

Short-acting Beta Agonist Bronchodilators

Country

l

o
m
a
t
u
b
l
a
S

e
n

i
l
a
t
u
b
r
e
T

l

o
r
e
t
o
n
e
F

e
n

i
l
a
n
e
r
p
i
c
r
O

l

o
r
e
t
o
r
p
e
R

l

o
r
e
t
u
b
r
a
C

e
n

i
l
a
n
e
r
p
o
x
e
H

l

o
r
e
t
u
b
r
i
P

l

o
r
e
t
u
b
n
e
l
C

l

o
r
e
t
l
o
t
i
B

l

o
r
e
t
a
c
o
r
P

Austria

Belgium

Cyprus

Czech Republic

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Ireland

Italy

Latvia

Lithuania

Luxembourg

Malta

Netherlands

Poland

Portugal

Norway

Slovak Republic

Slovenia

Spain

Sweden

United Kingdom

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp

4.8.2006

EN

Official Journal of the European Union

L 214/41

Table 2

Inhaled steroids

Beclomethasone Dexamethasone

Flunisolide

Fluticasone

Budesonide

Triamcinolone

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Country

Austria

Belgium

Cyprus

Czech Republic

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Ireland

Italy

Latvia

Lithuania

Luxembourg

Malta

Poland

Portugal

Netherlands

Norway

Slovak Republic

Slovenia

Spain

Sweden

United Kingdom

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp

L 214/42

EN

Official Journal of the European Union

4.8.2006

Table 3

Non-steroidal anti-inflammatories

Country

Cromoglicic
acid

Nedrocromil

Austria

Belgium

Cyprus

Czech Republic

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Ireland

Italy

Latvia

Lithuania

Luxembourg

Malta

Poland

Portugal

Netherlands

Norway

Slovak Republic

Slovenia

Spain

Sweden

United Kingdom

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp

4.8.2006

EN

Official Journal of the European Union

L 214/43

Table 4

Anticholinergic Bronchodilators

Country

Ipratropium
bromide

Oxitropium
Bromide

Austria

Belgium

Cyprus

Czech Republic

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Ireland

Italy

Latvia

Lithuania

Luxembourg

Malta

Netherlands

Poland

Portugal

Norway

Slovak Republic

Slovenia

Spain

Sweden

United Kingdom

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp

L 214/44

EN

Official Journal of the European Union

4.8.2006

Table 5

Long-acting Beta Agonist Bronchodilators

Formoterol

Salmeterol

X

X

X

Country

Austria

Belgium

Cyprus

Czech Republic

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Ireland

Italy

Latvia

Lithuania

Luxembourg

Malta

Netherlands

Poland

Portugal

Norway

Slovak Republic

Slovenia

Spain

Sweden

United Kingdom

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp

4.8.2006

EN

Official Journal of the European Union

L 214/45

Country

Combinations of active ingredients in a single MDI

Table 6

X

Austria

Belgium

Cyprus

Czech Republic

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Ireland

Italy

Latvia

Lithuania

Luxembourg

Malta

Netherlands

Poland

Portugal

Norway

Slovak Republic

Slovenia

Spain

Sweden

United Kingdom

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp

L 214/46

EN

Official Journal of the European Union

4.8.2006

ANNEX II

ESSENTIAL MEDICAL USES

Quota of controlled substances of Group I that may be used in the production of metered dose inhalers (MDIs) for the
treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:

3M Health Care (UK)
Bespak (UK)
Boehringer Ingelheim (DE)
on behalf of Boehringer Ingelheim France
Chiesi (IT)
IVAX (IE)
Lab Aldo-Union (ES)
Sicor (IT)
Valeas (IT)
V.A.R.I. (IT)

ANNEX III

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group I and II that may be used for laboratory and analytical uses, are allocated to:

Acros organics bvba (BE)
Bie & Berntsen (DK)
Biosolve (NL)
Carlo Erba Reactifs-SDS (FR)
CNRS — Groupe de Physique des Solides (FR)
Honeywell Fluorine Products Europe (NL)
Honeywell Specialty Chemicals (DE)
Ineos Fluor (UK)
Katholieke Universiteit Leuven (BE)
LGC Promochem (DE)
Mallinckrodt Baker (NL)
Merck KGaA (DE)
Mikro + Polo (SI)
Panreac Química (ES)
Sanolabor (SI)
Sigma Aldrich Chimie (FR)
Sigma Aldrich Company (UK)
Sigma Aldrich Logistik (DE)
Tazzetti Fluids (IT)
University of Technology Vienna (AT)

4.8.2006

EN

Official Journal of the European Union

L 214/47

ANNEX IV

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group III that may be used for laboratory and analytical uses are allocated to:

Airbus France (FR)
Ineos Fluor (UK)
Ministry of Defense (NL)
Sigma Aldrich Chimie (FR)

ANNEX V

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group IV that may be used for laboratory and analytical uses, are allocated to:

Acros Organics (BE)
Bie & Berntsen (DK)
Biosolve (NL)
Carlo Erba Reactifs-SDS (FR)
Health Protection Inspectorate-Laboratories (EE)
Institut Scientifique de Service Public (ISSeP) (BE)
Katholieke Universiteit Leuven (BE)
Mallinckrodt Baker (NL)
Merck KGaA (DE)
Mikro + Polo (SI)
Panreac Química (ES)
Sanolabor d.d. (SI)
Sigma Aldrich Chimie (FR)
Sigma Aldrich Company (UK)
Sigma Aldrich Laborchemikalien (DE)
Sigma Aldrich Logistik (DE)
VWR I.S.A.S. (FR)
YA-Kemia Oy (FI)

L 214/48

EN

Official Journal of the European Union

4.8.2006

ANNEX VI

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group V that may be used for laboratory and analytical uses are allocated to:

Acros Organics (BE)
Bie & Berntsen (DK)
Katholieke Universiteit Leuven (BE)
Mallinckrodt Baker (NL)
Merck KGaA (DE)
Mikro + Polo (SI)
Panreac Química (ES)
Sanolabor d.d. (SI)
Sigma Aldrich Chimie (FR)
Sigma Aldrich Company (UK)
Sigma Aldrich Logistik (DE)
YA-Kemia Oy (FI)

ANNEX VII

Quota of controlled substances of Group VI that may be used for laboratory and analytical critical uses are allocated to:

LABORATORY AND ANALYTICAL CRITICAL USES

Sigma-Aldrich Chemie GmbH (DE)

ANNEX VIII

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group VII that may be used for laboratory and analytical uses are allocated to:

Ineos Fluor (UK)
Katholieke Universiteit Leuven (BE)
Sigma Aldrich Logistik (FR)
Sigma Aldrich Company (UK)

4.8.2006

EN

Official Journal of the European Union

L 214/49

ANNEX IX

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group IX that may be used for laboratory and analytical uses are allocated to:

Ineos Fluor (UK)
Katholieke Universiteit Leuven (BE)
Sigma Aldrich Logistik (FR)
YA-Kemia Oy (FI)

[This Annex is not published because it contains confidential commercial information.]

ANNEX X